News | July 31, 2024
Barentz acquires Anshul Life Sciences to strengthen India portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The company is planning to expand its plant capacity in in Vapi
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Subscribe To Our Newsletter & Stay Updated
